Evidence map›Paper›PMID 40510231›Full record

ArticleIJID regions2025

Antibiotic resistance in empyema thoracis: clinical outcomes and contributing factors in a tertiary care setting in Pakistan.

Muhammad Umar, Sher Ali Khan

Abstract read
In one paragraph

Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Muhammad UmarDepartment of Pulmonology, Lady Reading Hospital, Peshawar, Pakistan.
Sher Ali KhanDepartment of Pulmonology, Lady Reading Hospital, Peshawar, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study aimed to determine the antibiotic resistance patterns, clinical outcomes, and factors influencing treatment outcomes in patients with empyema thoracis (ET). Methods: A total of 294 patients with ET (65.9% males, 34.1% females; mean age 47.9 ± 17.1 years) were included. Predisposing factors, comorbidities, microbial pathogens, and antibiotic resistance patterns were analyzed. Clinical improvement and associations with demographic and clinical variables were statistically evaluated. Results: Pulmonary parenchymal infection (68.2%) was the most common predisposing factor, followed by postoperative empyema (11.2%). Rural residency (64.3%), biomass exposure (71.0%), and non-smoking status (75.2%) were prevalent. Community-acquired empyema was observed in 72.2% of cases, and clinical improvement was achieved in 59.18%. Conclusions: ET remains a significant clinical challenge, with community-acquired infections and

Indexed as

Antibiotic resistanceClinical outcomesEmpyema thoracisPakistanPulmonary infections

Identifiers

PMID40510231
PMCPMC12159199

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.